Selank: the complete research guide.

Selank is a synthetic seven-amino-acid peptide built from tuftsin, an immune fragment. Russia has sold it as a prescription anxiety spray since 2009. No Western randomized trial has ever tested it. That gap is what you're really weighing whenever you read about Selank.

Among Russian-developed peptides, Selank and its sibling Semax sit in a category of their own. They aren't grey-market chemicals invented in a lab notebook in 2010. They're pharmaceuticals with decades of Russian clinical use and an active program at named Russian institutes. The preclinical work has run for over 20 years, much of it in Russian-language journals.

They also haven't crossed the Western regulatory wall. The Russian framework is different from the FDA's. And no Western drug company has funded the kind of Phase III trial that would turn Russian clinical experience into a US or EU approval.

Selank lands in a strange middle ground. It carries more evidence than a typical research compound and less than a Western-approved drug. Its place in global anxiety treatment is real and contested. We pulled 4 peer-reviewed Western studies for this guide, and here's what we found.

What is Selank, structurally?

Selank is a 7-residue peptide. The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first 4 residues are tuftsin, a natural immune-signaling tetrapeptide. Tuftsin gets made when an enzyme clips a piece off an antibody, immunoglobulin G, inside the spleen. It was first identified at Tufts University in the 1970s, which is where the name comes from.

Native tuftsin tells immune cells, mostly macrophages and neutrophils, to eat pathogens faster. Selank takes that tuftsin core and adds a 3-residue Pro-Gly-Pro tail. The tail resists enzymatic breakdown, which keeps the molecule around long enough for brain effects to be measurable.

That history matters. Selank isn't a "pure anxiety drug" the way a benzodiazepine is. It inherits an immune-modulating gene from its tuftsin parent. We read modern Russian research as treating it as a neuro-immune modulator, not a clean GABA drug. The cytokine data below is the strongest support for that framing.

The Selank development team is the central voice across nearly all of the published Russian literature. Myasoedov and Andreeva at the Institute of Molecular Genetics in Moscow have led it throughout. That tight authorship pattern is what makes Selank hard for us to judge from outside. The internal data is consistent, but independent labs outside Russia have published little.

What does the 2020 fMRI study show?

The most rigorous Western human study of Selank is the 2020 functional connectivity paper by Panikratova and colleagues, published in Doklady Biological Sciences. We dug into the methods and numbers.

The setup: 52 healthy adults in a placebo-controlled three-way design. Selank vs Semax vs placebo. Resting-state brain scans were taken before dosing, 5 minutes after, and 20 minutes after intranasal administration.

The main finding was a statistically significant change in the link between the right amygdala and several right temporal cortical regions. The amygdala is the brain's fear-and-threat hub. Those temporal regions handle emotion, memory and face recognition, which is exactly the network you'd expect an anxiolytic to touch.

This is real evidence and we think it's worth foregrounding. A brain-imaging finding in healthy volunteers isn't the same as proven anxiety-reduction in patients. But it establishes that the drug does something biologically detectable in the brain at a meaningful dose. That's more than most grey-market peptides can claim.

The limits are real too, and we want to be honest about them. Sample size was small at 52 participants. The imaging window was narrow: baseline, 5 minutes, 20 minutes. The outcome was a biomarker, not a clinical anxiety measure.

The design never tested sustained efficacy. It's a single well-executed data point showing target engagement. It isn't a substitute for the Phase III trial we'd want before anyone recommends Selank broadly.

Selank

Tuftsin analog 7 aa N-acetylated

The same compound cited across the 4 studies in this review. Lab-verified identity and purity.

Shop Selank

What does the animal research show?

The most direct animal evidence for an anti-anxiety effect comes from morphine-withdrawal experiments. Rats in opioid withdrawal show measurable anxiety behaviors: tactile sensitivity, drooping eyelids known as ptosis, abnormal posture, convulsions.

Konstantinopolsky and colleagues reported in 2022 that a single dose of Selank at 0.3 mg/kg cut the total withdrawal score by 39.6%. It eased convulsions, ptosis and posture problems. It raised the tactile sensitivity threshold 9-fold.

The reference drug in that experiment was diazepam, a benzodiazepine, at 2 mg/kg. Diazepam was slightly more potent than Selank at the doses tested.

The diazepam comparison is the most informative number in the dataset. A benzodiazepine at a meaningful rodent dose beat Selank, but not by much. Selank still produced a substantial anti-anxiety effect without the sedation, motor impairment or dependence that define benzodiazepines.

Take the animal data at face value and Selank sits in the benzodiazepine efficacy range on the anxiety axis. Its tolerability signal is noticeably cleaner. That's in rats, not people.

Is the immune-modulation real?

The cytokine data is the most distinctive piece of the Selank evidence base. Cytokines are messenger proteins the immune system uses to coordinate inflammatory responses. Chronic stress elevates multiple pro-inflammatory cytokines, and elevated inflammatory tone is a recognized correlate of treatment-resistant anxiety and depression in the research literature.

Yasenyavskaya and colleagues published a 2021 study in Current Reviews in Clinical and Experimental Pharmacology using a "social stress" rat model. Rats received Selank at 100 mcg/kg/day for 20 days while being exposed to chronic social conflict.

The result: Selank reduced stress-driven elevations in four pro-inflammatory cytokines, namely IL-1β, IL-6, TNF-α and TGF-β1. It also restored IL-4, an anti-inflammatory signal that chronic stress had suppressed. The pattern fits a tuftsin-derived molecule that kept its immune activity. It isn't a blunt anti-inflammatory. It normalizes stress-driven immune signals in context.

Inflammation-associated mood disorders are one of the more replicated findings in modern psychiatric research. If Selank really does normalize stress-driven cytokines, its mechanism may be more relevant to inflammation-flavored anxiety than to classical neurotransmitter-based GAD. That's a hypothesis the literature hasn't yet stress-tested in a proper clinical trial.

What about stress effects on the rest of the body?

Beyond the cytokine work, Selank shows stress-protective effects on the HPA axis and on gut tissue. The HPA axis is the brain-adrenal stress circuit.

Mukhina and colleagues reported in 2020 that Selank at 80, 250, or 750 mcg/kg in Wistar rats lowered stress-driven cortisol. It reduced colon-wall damage in restraint-stress models and helped rats adapt faster to repeated stress.

Those gut findings matter to the wider research interest in stress-driven GI conditions. Think IBS, functional dyspepsia and stress-triggered colitis flares. The cortisol effect fits what you'd expect from a neuro-immune modulator.

None of this is pivotal trial data. It does extend the preclinical picture coherently. Selank appears to dampen stress responses across several organ systems, not just behavior.

Why isn't there a Western RCT?

Selank's Russian approval is the thing that decides how much weight you should give it. The honest answer comes down to four factors.

First, Russian regulatory standards differ from Western ones. Russian approval can rest on smaller open-label or single-blind studies, often published only in Russian-language journals. Those studies wouldn't meet FDA or EMA standards. That isn't the same as saying the drug doesn't work. It's a statement about how high the evidentiary bar sits.

Second, no Western drug company has invested in a Phase III. The intellectual property is held by Russian institutions. The molecule has been off-patent for over 15 years in the structural sense. There's no commercial path for a Western pharma company to recoup a $100–200M trial investment.

Third, the global anxiety market is already crowded. SSRIs, SNRIs, and benzodiazepines are all generic, well-evidenced, and cheap. A new anxiety drug has a high bar to clear, and Phase III failure rates in CNS development run ~50%.

Fourth, Western trial infrastructure hasn't been pointed at Russian-market drugs. A few Russian-developed cancer drugs have crossed over. Those exceptions are rare.

The result is a molecule that's both more and less validated than its market position suggests. More, because it has a real Russian approval for a real indication and a coherent preclinical record. Less, because no Western Phase III exists for any indication, and the safety data isn't documented granularly in PubMed.

Selank

11 mg ≥99% pure Lyophilized

Tuftsin analog · 7 aa, N-acetylated. The same reference compound used across the cited preclinical studies. COA available with each lot.

Learn more

How does Selank compare to benzodiazepines?

The comparison Russian clinical literature draws most often is to medazepam, a Russian-tradition benzodiazepine. That data underpins the regulatory approval but isn't indexed in PubMed. It describes Selank as reducing anxiety about as well as medazepam, without the sedation, motor impairment or withdrawal. The 2022 morphine-withdrawal rodent study with diazepam is the closest English-language analog.

The claim advanced most often in the Russian literature is simple: benzodiazepine-class anxiety relief without the sedation and dependence. Selank's mechanism makes that biologically plausible. It combines allosteric GABA-system modulation with serotonergic and immune-modulatory activity.

No Western head-to-head trial has confirmed it. We'd treat the claim as a hypothesis supported by Russian clinical experience, not a conclusion established by randomized trial.

What's the side-effect profile?

Russian clinical experience describes Selank as well-tolerated at the approved nasal-spray dose in short-course anxiety studies. The most commonly reported adverse event in that literature is mild nasal irritation from the spray formulation. No major drug interactions, withdrawal syndrome, abuse potential, or meaningful sedation has been documented in the published Russian clinical record at approved doses.

Important caveats apply. First, Russian approval covers short-course use, typically days to weeks. No rigorous prospective design has studied long-term safety. Second, interactions with alcohol, benzodiazepines or other GABA-active agents are plausible in theory and undercharacterized in practice.

Third, lyophilized research powder isn't the approved nasal spray. Safety data from Russian clinical trials doesn't automatically carry across formulations. Fourth, reference-compound quality varies by supplier, so a lot-specific certificate of analysis and an identity check are standard practice.

What's the regulatory status?

Selank has been approved in Russia since 2009, as a nasal spray for generalized anxiety disorder. It is not approved by the FDA, EMA, or any other major Western agency. It isn't named on the WADA Prohibited List, and no major sports league bans it by name.

Absence from a list isn't permission. If you compete, verify with your governing body directly. We found no FDA enforcement actions specific to Selank. It sells in the US grey market as a research peptide, with the usual caveats around products not approved for human use.

How does the evidence base situate Selank relative to current anxiety pharmacology?

In the Western clinical literature, generalized anxiety disorder is managed mainly with cognitive behavioral therapy, which holds the strongest trial evidence. Then SSRIs and SNRIs, with moderate effect sizes and well-mapped tolerability. Then buspirone and short-course benzodiazepines.

Selank occupies a different niche. It's a neuro-immune modulator rather than a GABA full-agonist or a reuptake inhibitor. It also lacks the Western Phase III data you'd need to place it head-to-head against any of those drugs.

Selank leaves several research questions wide open.

• Translational validity of the 2020 fMRI finding. The Panikratova et al. amygdala connectivity result documents CNS engagement in healthy volunteers; whether that biomarker change predicts symptom reduction in a GAD population remains unstudied in Western cohorts.
• Russian clinical experience versus Western Phase III standards. The evidence gap between Russian regulatory approval and PubMed-indexed randomized trial data is the central unresolved question in the Selank literature.
• Reference standard and supply-chain purity. Russian pharmaceutical-grade Selank nasal spray and third-party tested lyophilized powder are not manufactured under identical conditions; published safety data derives from the former.
• Duration-of-use safety. Russian approval covers short-course use. Long-term administration has not been studied in rigorous prospective trials.
• Drug–drug interaction characterization. Interactions with GABA-active compounds, antidepressants, and other neuro-active agents remain clinically underexplored.